-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Practical Practice Recommendations for Lung Cancer Radiotherapy During the COVID-19 Pandemic: An ESTRO-ASTRO Consensus Statement
This webinar will give a summary of recently published ESTRO & ASTRO practice guidelines about radiotherapy for lung cancer in the COVID-19 pandemic, whether radiotherapy can or should be adapted, and if so how should this be done. We will address questions about whether radiotherapy can be delayed, fractionation of radiotherapy, multimodality treatment strategies and handling…
-
Member Story: Suraj Samtani Bassarmal
Dr. Suraj Samtani is a medical oncologist living and working in Santiago, Chile. I’m a medical oncologist and I also work in an intensive care unit in Santiago, Chile. In a country where subspecialists have always been on demand, great efforts on how to provide the best care to our patients are being implemented. COVID-19…
-
Disrupting the Paradigm: Partnering With Oncogene-Focused Patient Groups to Propel Research
Genomic alterations drive more than 60% of adenocarcinoma cases of NSCLC.1 Approximately 25% of these cases will have an oncogenic driver (EGFR, ALK, ROS1, BRAF, or NTRK) that can be treated with approved targeted therapy drugs, and more (such as MET, RET, and exon 20 insertions) have clinical trial options.1 Patients and caregivers dealing with…
-
-
-
Disparities in Meeting Eligibility Criteria for Lung Cancer Screening
By Kim L. Sandler, MD, Melinda C. Aldrich, MPH, PhD, and Jeffrey D. Blume, PhD Posted: April 16, 2020 IN REFERENCE TO: Aldrich MC, Mercaldo SF, Sandler KL, Blot WJ, Grogan EL, Blume JD. Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers. JAMA Oncol. 2019 Jun 27. [Epub ahead of print].…
-
Time to End the Debate on Genomic Testing in NSCLC
By Nathan Pennell, MD, PhD Posted: April 16, 2020 It’s an exciting time to be a thoracic oncologist. We live in an era of unprecedented discovery in medicine—and in oncology in particular—with basic scientific breakthroughs such as targetable driver oncogenes translating into highly effective treatments for patients in record time. In my relatively short career,…
-
Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade
By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field of lung cancer research. Treatment progress gained momentum and finally reached a tipping point in the mid-2010s, with the number of advances over the last…
-
A Cloud-Based Computerized System for the Korean Lung Cancer Screening Project
By Jin Mo Goo, MD, PhD, and Yeol Kim, MD, MPH, PhD Posted: April 16, 2020 Dr. Jin Mo Goo Dr. Yeol Kim In 2015, based on the evidence from the National Lung Screening Trial, the Korean multisociety collaborative committee developed and published a…
-
Liquid Biopsy’s Role in Marker Identification: An Interview With Dr. Martin Filipits
Posted: April 16, 2020 As we know, molecular marker identification allows for more rational use of existing therapies. When markers can be identified more effectively and quickly, patient care advances. In the following interview, Martin Filipits, PhD, discusses liquid biopsy’s role in marker identification and the downstream effects of its use. Dr. Filipits is a…